Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Miriam Richter Cohen"'
Autor:
Michael E. Luggen, M Weisman, Thomas Taylor, John J. Cush, William G. Henderson, Richard H. Ward, F. Paul Alepa, H. Ralph Schumacher, Grant W. Cannon, Miriam Richter Cohen, Elly Budiman-Mak, Joel Buxbaum, John R. Ward, Edwin Mejias, Daniel O. Clegg, Rama Makkena, F Vasey, Domenic J. Reda, Stuart L. Silverman, Maren L. Mahowald, Warren D. Blackburn, Robert J. Anderson, Clair M. Haakenson, B.J. Manaster
Publikováno v:
Arthritis and rheumatism. 39(12)
Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active ankylosing spondylitis (AS) that is not controlled with nonsteroidal antiinflammatory drug therapy. Methods. Two hundred sixty-fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feb73b20516827e73086de05b113ba17
https://pubmed.ncbi.nlm.nih.gov/8961905
https://pubmed.ncbi.nlm.nih.gov/8961905
Autor:
Richard H. Ward, Elly Budiman-Mak, Clair M. Haakenson, Grant W. Cannon, Daniel O. Clegg, John J. Cush, Nourollah Parhami, F. Paul Alepa, H. Ralph Schumacher, M Weisman, B.J. Manaster, Stuart L. Silverman, Dominic J. Balestra, Jean Higashida, Joel Buxbaum, John R. Ward, Warren D. Blackburn, F Vasey, Rama Makkena, Miriam Richter Cohen, Maren L. Mahowald, Robert D. Inman, Edwin Mejias, Robert J. Anderson, William G. Henderson, Domenic J. Reda
Publikováno v:
Arthritis and rheumatism. 39(12)
To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective in the treatment of reactive arthritis (ReA) that has been unresponsive to nonsteroidal antiinflammatory drug (NSAID) therapy.One hundred thirty-four patients with ReA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b7189438e693f677acf9a126369992b
https://pubmed.ncbi.nlm.nih.gov/9336437
https://pubmed.ncbi.nlm.nih.gov/9336437
Autor:
Miriam Richter Cohen
Publikováno v:
Arthritis and rheumatism. 37(11)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fe4598669f0604b4b82f4099d0b040a
https://pubmed.ncbi.nlm.nih.gov/7980683
https://pubmed.ncbi.nlm.nih.gov/7980683
Publikováno v:
Arthritis & Rheumatism. 32:734-740
Inclusion body myositis has been described as an inflammatory myopathy with distinctive clinical and pathologic features that is refractory to treatment. Ten cases of inclusion body myositis, as defined by histopathologic findings, were reviewed to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cea36ff2d2006c3444c30478a7da384
https://doi.org/10.1002/anr.1780320611
https://doi.org/10.1002/anr.1780320611